|
JP2020117455A
|
|
Pharmaceutical composition for prevention or treatment of skin disorders
|
|
JP2020111541A
|
|
Methods for producing trace element preparations
|
|
JP2019019112A
|
|
Sustained release formulation comprising 4-[5-(pyridin-4-yl)-1h-1,2,4-triazole-3-yl]pyridine-2-carbonitrile or salt thereof
|
|
JP2020158391A
|
|
Novel nitrocatechol derivative
|
|
JP2017193539A
|
|
Combination therapy agent
|
|
TW201728332A
|
|
Novel bisphosphonic acid compound
|
|
JP2018038962A
|
|
System and method for manufacturing grain-including composition
|
|
JP2016204351A
|
|
Pharmaceutical composition
|
|
JP2018039733A
|
|
Novel heterocyclic derivative
|
|
NZ702797A
|
|
Method for producing 4-[5-(pyridin-4-yl)-1h-1,2,4-triazol-3-yl]pyridine-2-carbonitrile, and intermediate thereof
|
|
JP2014180625A
|
|
Aseptic emulsification system
|
|
JP2014065697A
|
|
Novel carboxylic acid derivatives and prodrugs
|
|
JP2012246282A
|
|
Novel 2-phenylpropionic acid derivative
|
|
JP2011074017A
|
|
Novel phenol derivative
|
|
KR20100068651A
|
|
Novel 1, 2, 4-triazole compounds
|
|
JP2009143922A
|
|
Injection product
|
|
JP2009280561A
|
|
Parenteral injection
|
|
JP2009155315A
|
|
Injection product
|
|
JP2008088107A
|
|
New pyridazine derivative
|
|
JP2005139463A
|
|
Method for producing magnesium polycarbophil
|
